Tag: diabetes

UVA Center for Diabetes Technology and Novo Nordisk Entered Five-Year Research Collaboration

novo nordisk
University of Virginia (UVA) Center for Diabetes Technology and Novo Nordisk announced that they have entered into a five-year research collaboration where UVA and Novo Nordisk will work together on t...

Zydus Cadila Launced Vinglyn Brand Tabletes in India

Drug firm Zydus Cadila said it has launched its affordable oral anti-diabetic Vinglyn brand tablets available in two formulations in India. As the product patent on popular diabetes drug Vildaglipt...

Semaglutide as Add-On Therapy Proved to be Effective for Type 2 Diabetes Treatment

novo nordisk
The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of oral semaglutide (Rybelsus® Novo Nordisk), a GLP-1 recep...

European Commission Approved AstraZeneca Qtrilmet

diabetes
AstraZeneca announced that the European Commission has approved Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets to improve glycaemic control in adults with t...

FDA Advisory Committee Voted Against Empagliflozin as Adjunct to Insulin for Adults with Type 1 Diab...

diabetes drugs
The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support a...

Abbott and Omada Health Partnering to Integrate FreeStyle Libre System

abbott
Abbott and Omada Health announced they are partnering to integrate Abbott's revolutionary FreeStyle Libre system, a continuous glucose monitoring (CGM) technology, with Omada Health's pioneering digit...

Sanofi to Launch Its Type II Diabetes Treatment in UK

sanofi
Sanofi has launched Suliqua (insulin glargine/lixisenatide), its type II diabetes treatment, in the UK. The approval of the once-daily injection is based on two phase III studies, LixiLan-O and Lix...

Novo Nordisk Rybelsus Approved by FDA

The U.S. Food and Drug Administration approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is t...

Poor Diabetes Control Costs NHS £3bn

New research finds that poor diabetes control costs the NHS £3bn in potentially avoidable hospital treatment in England. The findings, being presented at this year’s European Association for the St...

Sanofi Will Pay to Lexicon for Partnership Termination

Lexicon Pharmaceuticals Inc said on Tuesday that France’s Sanofi SA will pay the drugmaker $260 million for the termination of their partnership to develop diabetes drug Zynquista. Shares of Lexico...

Xeris Received FDA Approval for Diabetes Ready-to-Use Injection

Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, announce...

Novo Nordisk to Offer Cheaper Insulin to U.S. Diabetics

novo nordisk
Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi ...

ESC Published New Clinical Practice Guidelines on the Management of Diabetes and CCS

The European Society of Cardiology (ESC) has published new clinical practice guidelines on the management of diabetes and ‘chronic coronary syndromes (CCS)’, which replace the 2013 recommendations for...

EU Granted Extension of the Indication for Novo Nordisk Fiasp®

Novo Nordisk
Novo Nordisk announced that the European Commission has granted an extension of the indication for Fiasp® (fast-acting insulin aspart), approving it for the treatment of diabetes in adolescents and ch...

Sanofi Terminated Partnership with Lexicon

diabetes drugs
French drugmaker Sanofi SA said it had terminated its partnership with Lexicon Pharmaceuticals Inc to develop a drug for use with insulin in patients with type 1 and type 2 diabetes. Shares of Lexi...

Merck and Utah University Found Potential Drug Target for Diabetes

Merck Research Laboratories and the University of Utah Health have shown that deactivation of the dihydroceramide desaturase 1 (DES1) enzyme could offer a potential drug target for metabolic diabetes....